Dublin, Jan. 19, 2022 (GLOBE NEWSWIRE) -- The "The World Liquid Biopsy Market 2021" report has been added to ResearchAndMarkets.com's offering.

While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.

This report contains up-to-date information and useful data points for business planning:

• Research vs. Clinical Liquid Biopsy

• The Market for Liquid Biopsy by Region

• The Market for Liquid Biopsy Market by Type of Analyte

• The Market for CTC-based Liquid Biopsy

• The Market for ctDNA-based Liquid Biopsy

• The Market for EV and Exosome-based Liquid Biopsy

• The Market for Multi-Analyte-based Liquid Biopsy

• The Market for Other Liquid Biopsy

• Liquid Biopsy Market by Type of Cancer (Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, Other Cancer)

• Selected ctDNA-based Liquid Biopsy Tests in Development

• Selected Market-Available CTC-based Liquid Biopsy Tests, 2021

• Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021

Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:

• Early detection and diagnosis/screening

• Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown

• Therapy personalization and monitoring - by molecular characterization of a patient's disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise

• Disease monitoring - to observe disease progression, tumor evolution, residual disease, and early detection of recurrence

• Prognosis of disease

Key Topics Covered:

CHAPTER 1: EXECUTIVE SUMMARY
INTRODUCTION
LIQUID BIOPSY TECHNOLOGIES
INDUSTRY STRUCTURE
LIQUID BIOPSY MARKET REVENUES AND FORECAST

CHAPTER 2: LIQUID BIOPSY TECHNOLOGIES
INTRODUCTION
CURRENT MAJOR LIQUID BIOPSY TECHNOLOGIES

CHAPTER 3: CIRCULATING TUMOR DNA (CTDNA) LIQUID BIOPSY
INTRODUCTION
ADVANTAGES AND LIMITATIONS OF CTDNA IN LIQUID BIOPSY
CURRENT CTDNA-BASED LIQUID BIOPSY TESTS

• Biocartis

• Biocept

• Biodesix

• CellMax Life

• Circulogene

• Diacarta

• Epigenomics

• Foundation Medicine (Roche)

• Guardant Health

• Inivata (Neogenomics)

• LungLife AI

• Myriad Genetics

• NeoGenomics

• OncoDNA

• Personal Genomic Diagnostics

• QIAGEN

• Resolution Biosciences

• Roche Diagnostics

• Sysmex-Inostics

• Tempus

CTDNA-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT

• Exact Sciences

• Freenome

• GRAIL

• Neogenomics

CHAPTER 4: CIRCULATING TUMOR CELLS (CTCS) LIQUID BIOPSY
INTRODUCTION
CHALLENGES IN THE DEVELOPMENT OF CTC-BASED LIQUID BIOPSY TESTS
CTC-BASED LIQUID BIOPSY TESTS

• Adaptive Biotechnologies

• Biocept

• CellMax Life

• Epic Sciences

• GILUPI

• LungLife AI

• Menarini-Silicon Biosystems

• QIAGEN

CTC-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT

ANGLE
Epic Sciences
Liquid Biotech USA

CHAPTER 5: EXTRACELLULAR VESICLES AND OTHER LIQUID BIOPSY
INTRODUCTION
LIQUID BIOPSY TESTS BASED ON EXTRACELLULAR VESICLES/OTHER ANALYTES

• Aspira Women's Health (formerly Vermillion)

• Biodesix

• Exosome Diagnostics

• Hologic

• MDxHealth

EXTRACELLULAR VESICLE/OTHER ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT

• Circulogene

• OncoCyte

• Resolution Biosciences

• VolitionRx

CHAPTER 6: MULTI-ANALYTE LIQUID BIOPSY TESTS
LIQUID BIOPSY TESTS BASED ON MULTIPLE ANALYTES

• Biocept

• Biodesix

• Foundation Medicine (Roche)

• LungLife AI

• NeoGenomics

• OncoDNA

MULTIPLE ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT

• Exact Sciences

• Freenome

• GRAIL

• LungLife AI

CHAPTER 7: LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY
INTRODUCTION
LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY

• Agena Bioscience

• ANGLE

• DiaCarta

• Exosome Diagnostics

• Guardant Health

• Natera

• QIAGEN

CHAPTER 8: LIQUID BIOPSY INDUSTRY ANALYSIS
TIERS OF COMPETITION
COMPETITIVE FACTORS
SIGNIFICANT MARKET TRENDS

• Personalized Medicine

• Increasing Global Life Expectancy

• New Liquid Biopsy Products

• Increasing Accessibility of Genetic Testing

• Regulatory Hurdles

• Third-Party Payor Coverage

• Demonstrated Clinical Utility

• Incidence Rates of Specific Cancers

COMPETITORS NO LONGER IN THE LIQUID BIOPSY MARKET

CHAPTER 9: LIQUID BIOPSY MARKET
MARKET OVERVIEW
MARKET FORECAST

CHAPTER 10: MARKET BY ANALYTE CIRCULATING TUMOR DNA

CIRCULATING TUMOR CELLS
EXTRACELLULAR VESICLES AND OTHER ANALYTES
MULTIPLE ANALYTES

• Market Overview

• Applications

• Technologies

• Specimens

• Revenue Forecast

CHAPTER 11: MARKET BY APPLICATION
THERAPY GUIDANCE AND MONITORING
DIAGNOSIS/SCREENING
DISEASE PROGNOSIS

• Market Overview

• Revenue Forecast

CHAPTER 12: MARKET BY CANCER TYPE
BREAST CANCER
COLORECTAL CANCER
LUNG CANCER
OVARIAN CANCER
PROSTATE CANCER
OTHER CANCERS:Including bladder, gastrointestinal, pancreatic, renal, melanoma and hematological malignancies.

• Market Overview

• Revenue Forecast

PAN-CANCER TESTS

• Market Overview

• Revenue Forecast

CHAPTER 13: LIQUID BIOPSY COMPANY PROFILES
TOP TEN COMPANIES IN THE LIQUID BIOPSY MARKET

Companies Mentioned

• Adaptive Biotechnologies

• Agena Bioscience, Inc.

• Angle, plc

• Aspira Women'S Health

• Biocartis Group Nv

• Biocept, Inc.

• Biodesix

• Cellmax Life

• Circulogene

• Diacarta, Inc.

• Epic Sciences

• Epigenomics AG

• Exact Sciences

• Exosome Diagnostics, Inc.

• Foundation Medicine, Inc. (Roche)

• Freenome, Inc.

• Gilupi GmbH

• Grail (Illumina)

• Guardant Health, Inc.

• Hologic

• Lunglife Ai (Formerly Cynvenio Biosystems)

• Mdxhealth

• Menarini-Silicon Biosystems, Spa

• Myriad Genetics, Inc.

• Natera, Inc.

• Neogenomics Laboratories, Inc.

• Oncocyte Corporation

• Oncodna S.A.

• Oncimmune

• Personal Genome Diagnostics

• Predicineq2 Solutionsqiagen N.V.

• Cell-Free Dna Technologies

• Ctc Technologies

• Exosome and Mirna Technologies

• Resolution Biosciences (Agilent)

• Roche Diagnostics

• Stagezero Life Sciences

• Sysmex-Inostics, Inc.

• Tempus

• Veracyte

• Volitionrx

For more information about this report visit https://www.researchandmarkets.com/r/s2sb36

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900